Apollo Therapeutics

7 articles about Apollo Therapeutics

• Apollo Therapeutics and The Institute of Cancer Research enter into collaboration for cancer drug development

  11/14/2022

  Apollo Therapeutics, a portfolio biopharmaceutical company focusing on translational biology and drug development, and The Institute of Cancer Research, London, a world-leading cancer research organisation, announce they have entered into a strategic collaboration to discover and develop new cancer medicines.

• Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics

  8/1/2022

  Avalo Therapeutics, Inc. (Nasdaq: AVTX) and Apollo Therapeutics Group Limited have entered into a worldwide, exclusive license agreement granting rights to Apollo to research, develop, manufacture and commercialize AVTX-007.

• Apollo Therapeutics and King’s College London Enter Into a Strategic Collaboration

  2/22/2022

  Apollo Therapeutics, a biopharmaceutical company focused on translational biology and asset-centric drug development, and King’s College London, announced the formation of a new strategic collaboration.

• Apollo Therapeutics Appoints Dr. Sanjay Aggarwal as Chief Medical Officer, Opens U.S. Facility

  11/18/2021

  Apollo Therapeutics today announced the appointment of Dr. Sanjay Aggarwal as the company’s chief medical officer.

• Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Advance Portfolio-Based Drug Development

  6/17/2021

  Apollo Therapeutics, a portfolio-based biopharmaceutical company rapidly advancing potentially transformative treatments based on breakthrough discoveries, has completed a $145 million financing.

• UCLB and Apollo Therapeutics secure first out-licensing deal to Deerfield, a leading U.S. healthcare investment firm

  7/20/2020

  UCL Business (UCLB) and Apollo Therapeutics (Apollo), a pioneering collaboration between three global pharmaceutical companies and three UK university technology transfer offices, along with Deerfield Management Company, have completed the licensing of the first Apollo-supported project, a novel gene therapy programme developed at University College London (UCL).

• Apollo Therapeutics: Dr Richard Butt Appointed CEO

  4/14/2016